Q32 Bio reports 36-week SIGNAL-AA data for bempikibart in severe alopecia areata

Q32 Bio announced additional 36-week results and initial findings from the 16-week off-drug period of Part B of its SIGNAL-AA Phase 2a trial of bempikibart in patients with severe or very severe alopecia areata. The company said clinically meaningful efficacy was observed on primary and key secondary endpoints at week 36, with durable maintenance and deepening of response.

Detected & updated continuously · Source: Nebula